Tax

Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories

Retrieved on: 
Friday, March 1, 2024

Kinnate has entered into an Asset Purchase Agreement (the “APA”) with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program assets.

Key Points: 
  • Kinnate has entered into an Asset Purchase Agreement (the “APA”) with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program assets.
  • SAN FRANCISCO, SAN DIEGO and CASTRES, France, March 01, 2024 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc .
  • (Nasdaq: KNTE) (“Kinnate” or the “Company”), a clinical-stage precision oncology company, and Pierre Fabre Médicament, SAS (“Pierre Fabre Laboratories”), a global player in oncology, today announced their agreement to the sale of the Company’s investigational pan-RAF inhibitor, exarafenib, and other pan-RAF program assets pursuant to the APA entered into by the parties.
  • In addition, Pierre Fabre Laboratories will assume up to $5 million of trade payables for the transferred assets.

Vallourec Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Friday, March 1, 2024

In Q4 2023, Vallourec recorded a €153 million income related to the reversal of previously-booked impairments.

Key Points: 
  • In Q4 2023, Vallourec recorded a €153 million income related to the reversal of previously-booked impairments.
  • In Q4 2023, Vallourec recorded a (€185) million charge predominantly related to its restructuring efforts in Germany.
  • Over the full year 2023, Vallourec recorded revenues of €5,114 million, up 5% year-on-year (+6% at constant exchange rates).
  • This estimate includes the impact of the provisions and charges recorded in Fourth Quarter 2023.

Middlesex Water Announces 2023 Year End Results

Retrieved on: 
Thursday, February 29, 2024

ISELIN, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Middlesex Water Company (“Middlesex” or the “Company”) (NASDAQ:MSEX) today announced financial results for the year ended December 31, 2023.

Key Points: 
  • ISELIN, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Middlesex Water Company (“Middlesex” or the “Company”) (NASDAQ:MSEX) today announced financial results for the year ended December 31, 2023.
  • Consolidated operating revenues increased to $166.3 million for the year ended December 31, 2023, up $3.8 million from 2022.
  • Lower weather-related main break activity in our Middlesex System offset some of these increased expenses.
  • Middlesex recognized a $5.2 million gain on the sale of its regulated Delaware wastewater subsidiary in January 2022.

Ross Acquisition Corp II Announces Meeting for Shareholders to Extend Date for Business Combination

Retrieved on: 
Thursday, February 29, 2024

The Extension Amendment Proposal is described in more detail in the Definitive Proxy Statement.

Key Points: 
  • The Extension Amendment Proposal is described in more detail in the Definitive Proxy Statement.
  • Beneficial owners of Public Shares held in “street name,” however, will not need to take any action in order to receive the redemption amount.
  • The proceeds of the Trust Account will be held in a non-interest bearing account while awaiting disbursement.
  • The Company’s initial shareholders have waived their redemption rights with respect to the outstanding Class B ordinary shares issued prior to the Company’s initial public offering.

CubeSmart Reports Fourth Quarter and Annual 2023 Results

Retrieved on: 
Thursday, February 29, 2024

Net income attributable to the Company’s common shareholders was $112.7 million for the fourth quarter of 2023, compared with $81.9 million for the fourth quarter of 2022.

Key Points: 
  • Net income attributable to the Company’s common shareholders was $112.7 million for the fourth quarter of 2023, compared with $81.9 million for the fourth quarter of 2022.
  • FFO, as adjusted, was $158.4 million for the fourth quarter of 2023, compared with $152.3 million for the fourth quarter of 2022.
  • Same-store revenues for the fourth quarter of 2023 increased 0.4% and same-store operating expenses decreased 1.8% from the same quarter in 2022.
  • Same-store NOI increased 1.2% from the fourth quarter of 2022 to the fourth quarter of 2023.

Zscaler Reports Second Quarter Fiscal 2024 Financial Results

Retrieved on: 
Thursday, February 29, 2024

SAN JOSE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Zscaler, Inc. (Nasdaq: ZS), the leader in cloud security, today announced financial results for its second quarter of fiscal year 2024, ended January 31, 2024.

Key Points: 
  • SAN JOSE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Zscaler, Inc. (Nasdaq: ZS), the leader in cloud security, today announced financial results for its second quarter of fiscal year 2024, ended January 31, 2024.
  • Non-GAAP income from operations was $103.2 million, or 20% of revenue, compared to $48.8 million, or 13% of revenue, in the second quarter of fiscal 2023.
  • Non-GAAP net income per share was $0.76, compared to $0.37 in the second quarter of fiscal 2023.
  • Zscaler will host a conference call for analysts and investors to discuss its second quarter of fiscal 2024 and outlook for its third quarter of fiscal 2024 and full year fiscal 2024 today at 1:30 p.m. Pacific time (4:30 p.m. Eastern time).

Cronos Group Reports 2023 Fourth Quarter and Full-Year Results¹

Retrieved on: 
Thursday, February 29, 2024

In Israel, Cronos launched three new flower offerings under the Peace Naturals® brand in the fourth quarter, Rockstar, Dancehall, and Sonic Fuel.

Key Points: 
  • In Israel, Cronos launched three new flower offerings under the Peace Naturals® brand in the fourth quarter, Rockstar, Dancehall, and Sonic Fuel.
  • Cronos GrowCo reported to the Company preliminary unaudited net revenue to licensed producers excluding sales to the Company in the fourth quarter and full-year 2023 of approximately $6.6 million and $19.6 million, respectively.
  • In addition to principal repayment, Cronos also received approximately $10.3 million in interest payments from GrowCo in 2023, resulting in a total of approximately $15.9 million in cash payments to Cronos in 2023.
  • ET to discuss 2023 Fourth Quarter and Full-Year business results.

Studio City International Holdings Limited Announces Unaudited Fourth Quarter 2023 Earnings

Retrieved on: 
Thursday, February 29, 2024

Studio City Casino’s rolling chip volume was US$566.0 million in the fourth quarter of 2023 versus US$251.4 million in the fourth quarter of 2022.

Key Points: 
  • Studio City Casino’s rolling chip volume was US$566.0 million in the fourth quarter of 2023 versus US$251.4 million in the fourth quarter of 2022.
  • Total non-gaming revenues at Studio City for the fourth quarter of 2023 were US$84.3 million, compared with US$16.7 million for the fourth quarter of 2022.
  • Net loss attributable to Studio City International Holdings Limited for the fourth quarter of 2023 was US$18.6 million, compared with net loss attributable to Studio City International Holdings Limited of US$85.4 million in the fourth quarter of 2022.
  • Net loss attributable to Studio City International Holdings Limited for 2023 was US$133.5 million, compared with net loss attributable to Studio City International Holdings Limited of US$326.5 million for 2022.

California Water Service Group Announces 2023 Earnings for Year and Fourth Quarter

Retrieved on: 
Thursday, February 29, 2024

Operating revenue in 2023 was $794.6 million, a $51.8 million decrease from 2022 operating revenue of $846.4 million.

Key Points: 
  • Operating revenue in 2023 was $794.6 million, a $51.8 million decrease from 2022 operating revenue of $846.4 million.
  • Total operating expenses in 2023 were $717.5 million, a $1.3 million decrease from 2022 operating expenses of $718.8 million.
  • Income tax benefit for the fourth quarter of 2023 increased $11.2 million to $13.8 million compared to the fourth quarter of 2022.
  • In the fourth quarter of 2023, net other income increased $2.7 million to $7.0 million from $4.3 million in the fourth quarter of 2022.

Definitive Healthcare Reports Financial Results for Fourth Quarter and Full Fiscal Year 2023

Retrieved on: 
Wednesday, February 28, 2024

FRAMINGHAM, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter and full year ended December 31, 2023. 

Key Points: 
  • FRAMINGHAM, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter and full year ended December 31, 2023.
  • Fourth Quarter 2023 Financial Highlights:
    Revenue was $65.9 million, an increase of 9% from $60.6 million in Q4 2022.
  • Full Year 2023 Financial Highlights:
    Revenue was $251.4 million for the year, an increase of 13% from $222.7 million for the full year 2022.
  • Definitive Healthcare will host a conference call on February 28, 2024, at 5:00 p.m. (Eastern Time) to discuss the Company's full financial results and current business outlook.